DK4370116T3 - Aficamten-doseringsregimer til behandling af obstruktiv hypertrofisk kardiomyopati - Google Patents
Aficamten-doseringsregimer til behandling af obstruktiv hypertrofisk kardiomyopati Download PDFInfo
- Publication number
- DK4370116T3 DK4370116T3 DK22753953.3T DK22753953T DK4370116T3 DK 4370116 T3 DK4370116 T3 DK 4370116T3 DK 22753953 T DK22753953 T DK 22753953T DK 4370116 T3 DK4370116 T3 DK 4370116T3
- Authority
- DK
- Denmark
- Prior art keywords
- aficamten
- treatment
- hypertrophic cardiomyopathy
- dosage regime
- obstructive hypertrophic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Display Devices Of Pinball Game Machines (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163203333P | 2021-07-16 | 2021-07-16 | |
| US202263299753P | 2022-01-14 | 2022-01-14 | |
| US202263305609P | 2022-02-01 | 2022-02-01 | |
| US202263331197P | 2022-04-14 | 2022-04-14 | |
| US202263343975P | 2022-05-19 | 2022-05-19 | |
| PCT/US2022/073808 WO2023288324A1 (en) | 2021-07-16 | 2022-07-15 | Methods for treating hypertrophic cardiomyopathy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK4370116T3 true DK4370116T3 (da) | 2025-02-03 |
Family
ID=82850823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK22753953.3T DK4370116T3 (da) | 2021-07-16 | 2022-07-15 | Aficamten-doseringsregimer til behandling af obstruktiv hypertrofisk kardiomyopati |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US20230058927A1 (https=) |
| EP (2) | EP4548912A3 (https=) |
| JP (1) | JP2024526334A (https=) |
| KR (1) | KR20240047359A (https=) |
| AU (1) | AU2022312506A1 (https=) |
| CA (1) | CA3225787A1 (https=) |
| CL (2) | CL2024000090A1 (https=) |
| DK (1) | DK4370116T3 (https=) |
| ES (1) | ES3014965T3 (https=) |
| FI (1) | FI4370116T3 (https=) |
| HR (1) | HRP20250174T1 (https=) |
| HU (1) | HUE070699T2 (https=) |
| IL (1) | IL310140A (https=) |
| LT (1) | LT4370116T (https=) |
| MX (1) | MX2024000804A (https=) |
| PL (1) | PL4370116T3 (https=) |
| PT (1) | PT4370116T (https=) |
| RS (1) | RS66640B1 (https=) |
| SI (1) | SI4370116T1 (https=) |
| SM (1) | SMT202500098T1 (https=) |
| TW (1) | TW202320763A (https=) |
| WO (1) | WO2023288324A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019144041A1 (en) | 2018-01-19 | 2019-07-25 | Cytokinetics, Inc. | Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors |
| JP7610985B2 (ja) | 2018-06-26 | 2025-01-09 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| JP7438148B2 (ja) | 2018-06-26 | 2024-02-26 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| PT4370116T (pt) | 2021-07-16 | 2025-03-14 | Cytokinetics Inc | Regimes de administração de aficamten para o tratamento da cardiomiopatia hipertrófica obstrutiva |
| EP4565230A1 (en) * | 2022-08-04 | 2025-06-11 | Cytokinetics, Inc. | Methods for treating obstructive hypertrophic cardiomyopathy |
| WO2024182469A1 (en) * | 2023-02-28 | 2024-09-06 | MyoKardia, Inc. | Myosin inhibitors for use in the treatment of hypertrophic cardiomyopathy |
| WO2024179422A1 (zh) * | 2023-03-02 | 2024-09-06 | 苏州科睿思制药有限公司 | Aficamten的共晶及其制备方法和用途 |
| US20250295639A1 (en) | 2024-03-20 | 2025-09-25 | Cytokinetics, Incorporated | Methods for treating heart diseases |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060292695A1 (en) * | 2005-06-22 | 2006-12-28 | Roslin Institute | Methods and kits for drug screening and toxicity testing using promoter-reporter cells derived from embryonic stem cells |
| CA3071948A1 (en) * | 2017-08-04 | 2019-02-07 | MyoKardia, Inc. | Mavacamten for use in the treatment of hypertrophic cardiomyopathy |
| WO2019144041A1 (en) | 2018-01-19 | 2019-07-25 | Cytokinetics, Inc. | Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors |
| WO2020257609A1 (en) | 2019-06-21 | 2020-12-24 | MyoKardia, Inc. | Diagnostics and treatments for cardiac disease |
| RS65302B1 (sr) | 2019-07-17 | 2024-04-30 | Cytokinetics Inc | Oralne formulacije inhibitora srčanog sarkomera |
| EP3999180B1 (en) | 2019-07-17 | 2024-05-08 | Cytokinetics, Inc. | Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide |
| EP4054588A4 (en) | 2019-11-10 | 2023-12-13 | MyoKardia, Inc. | Methods of treatment with myosin modulator |
| MX2023002024A (es) | 2020-08-28 | 2023-05-10 | Myokardia Inc | Métodos de tratamiento con modulador de miosina. |
| CN114456163B (zh) | 2020-11-09 | 2023-08-11 | 江苏恒瑞医药股份有限公司 | 四氢吡啶并嘧啶二酮类衍生物、其制备方法及其在医药上的应用 |
| CN114516843B (zh) | 2020-11-19 | 2024-10-22 | 江苏恒瑞医药股份有限公司 | 嘧啶二酮类衍生物、其制备方法及其在医药上的应用 |
| WO2022105852A1 (zh) | 2020-11-20 | 2022-05-27 | 江苏恒瑞医药股份有限公司 | 三嗪二酮类衍生物、其制备方法及其在医药上的应用 |
| CN114539257B (zh) | 2020-11-24 | 2023-08-11 | 江苏恒瑞医药股份有限公司 | 嘧啶二酮类螺环衍生物、其制备方法及其在医药上的应用 |
| CN114539229B (zh) | 2020-11-24 | 2024-10-22 | 江苏恒瑞医药股份有限公司 | 嘧啶二酮类衍生物、其制备方法及其在医药上的应用 |
| CN116507621B (zh) | 2020-11-24 | 2025-10-17 | 江苏恒瑞医药股份有限公司 | 嘧啶二酮类衍生物、其制备方法及其在医药上的应用 |
| PT4370116T (pt) | 2021-07-16 | 2025-03-14 | Cytokinetics Inc | Regimes de administração de aficamten para o tratamento da cardiomiopatia hipertrófica obstrutiva |
| MX2024001294A (es) | 2021-08-03 | 2024-02-13 | Cytokinetics Inc | Proceso para la preparacion de aficamten. |
| EP4514355A1 (en) | 2022-04-26 | 2025-03-05 | MyoKardia, Inc. | Methods of administering myosin inhibitors |
| WO2024020468A1 (en) | 2022-07-20 | 2024-01-25 | Cytokinetics, Incorporated | Methods for treating non-obstructive hypertrophic cardiomyopathy |
| EP4565230A1 (en) | 2022-08-04 | 2025-06-11 | Cytokinetics, Inc. | Methods for treating obstructive hypertrophic cardiomyopathy |
| WO2024050139A1 (en) | 2022-09-02 | 2024-03-07 | AnaBios Corporation | Therapeutic uses of cardiac myosin inhibitors |
| CN120187352A (zh) | 2022-10-21 | 2025-06-20 | 普若莱奥公司 | 治疗肥厚型心肌病的系统和方法 |
| WO2024097284A1 (en) | 2022-11-02 | 2024-05-10 | MyoKardia, Inc. | Mavacamten and derivatives thereof for use in treating atrial dysfunction |
| WO2024134498A1 (en) | 2022-12-22 | 2024-06-27 | Assia Chemical Industries Ltd. | Solid state forms of aficamten and process for preparation thereof |
| WO2024173765A1 (en) | 2023-02-17 | 2024-08-22 | Bristol Myers Squibb Company | Methods of prognosis and treatment for heart failure with preserved ejection fraction using urinary protein levels |
| WO2024182469A1 (en) | 2023-02-28 | 2024-09-06 | MyoKardia, Inc. | Myosin inhibitors for use in the treatment of hypertrophic cardiomyopathy |
| WO2024179422A1 (zh) | 2023-03-02 | 2024-09-06 | 苏州科睿思制药有限公司 | Aficamten的共晶及其制备方法和用途 |
| WO2025096779A2 (en) | 2023-11-01 | 2025-05-08 | Bristol Myers Squibb Company | Methods of treatment with a myosin inhibitor using protein levels |
-
2022
- 2022-07-15 PT PT227539533T patent/PT4370116T/pt unknown
- 2022-07-15 LT LTEPPCT/US2022/073808T patent/LT4370116T/lt unknown
- 2022-07-15 FI FIEP22753953.3T patent/FI4370116T3/fi active
- 2022-07-15 EP EP25151678.7A patent/EP4548912A3/en active Pending
- 2022-07-15 AU AU2022312506A patent/AU2022312506A1/en active Pending
- 2022-07-15 HR HRP20250174TT patent/HRP20250174T1/hr unknown
- 2022-07-15 PL PL22753953.3T patent/PL4370116T3/pl unknown
- 2022-07-15 MX MX2024000804A patent/MX2024000804A/es unknown
- 2022-07-15 IL IL310140A patent/IL310140A/en unknown
- 2022-07-15 CA CA3225787A patent/CA3225787A1/en active Pending
- 2022-07-15 WO PCT/US2022/073808 patent/WO2023288324A1/en not_active Ceased
- 2022-07-15 JP JP2024501787A patent/JP2024526334A/ja active Pending
- 2022-07-15 HU HUE22753953A patent/HUE070699T2/hu unknown
- 2022-07-15 DK DK22753953.3T patent/DK4370116T3/da active
- 2022-07-15 SM SM20250098T patent/SMT202500098T1/it unknown
- 2022-07-15 KR KR1020247002855A patent/KR20240047359A/ko active Pending
- 2022-07-15 SI SI202230095T patent/SI4370116T1/sl unknown
- 2022-07-15 US US17/812,994 patent/US20230058927A1/en not_active Abandoned
- 2022-07-15 EP EP22753953.3A patent/EP4370116B1/en active Active
- 2022-07-15 TW TW111126631A patent/TW202320763A/zh unknown
- 2022-07-15 ES ES22753953T patent/ES3014965T3/es active Active
- 2022-07-15 RS RS20250239A patent/RS66640B1/sr unknown
-
2024
- 2024-01-10 CL CL2024000090A patent/CL2024000090A1/es unknown
- 2024-06-25 CL CL2024001945A patent/CL2024001945A1/es unknown
- 2024-10-08 US US18/909,401 patent/US12370179B1/en active Active
- 2024-10-15 US US18/916,215 patent/US20250177357A1/en active Pending
-
2025
- 2025-07-01 US US19/257,352 patent/US20260097021A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PL4370116T3 (pl) | 2025-04-28 |
| EP4370116B1 (en) | 2025-01-15 |
| HUE070699T2 (hu) | 2025-06-28 |
| MX2024000804A (es) | 2024-02-06 |
| CA3225787A1 (en) | 2023-01-19 |
| RS66640B1 (sr) | 2025-04-30 |
| SI4370116T1 (sl) | 2025-04-30 |
| US20250177357A1 (en) | 2025-06-05 |
| FI4370116T3 (fi) | 2025-03-04 |
| CL2024001945A1 (es) | 2024-12-06 |
| SMT202500098T1 (it) | 2025-03-12 |
| IL310140A (en) | 2024-03-01 |
| KR20240047359A (ko) | 2024-04-12 |
| EP4548912A3 (en) | 2025-07-02 |
| JP2024526334A (ja) | 2024-07-17 |
| CL2024000090A1 (es) | 2024-08-16 |
| AU2022312506A1 (en) | 2024-02-01 |
| EP4370116A1 (en) | 2024-05-22 |
| US12370179B1 (en) | 2025-07-29 |
| WO2023288324A1 (en) | 2023-01-19 |
| PT4370116T (pt) | 2025-03-14 |
| LT4370116T (lt) | 2025-04-10 |
| ES3014965T3 (en) | 2025-04-28 |
| US20260097021A1 (en) | 2026-04-09 |
| EP4548912A2 (en) | 2025-05-07 |
| HRP20250174T1 (hr) | 2025-04-11 |
| TW202320763A (zh) | 2023-06-01 |
| US20230058927A1 (en) | 2023-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK4370116T3 (da) | Aficamten-doseringsregimer til behandling af obstruktiv hypertrofisk kardiomyopati | |
| DK3661514T3 (da) | Mavacamten til behandling af hypertrofisk kardiomyopati | |
| EP4058032A4 (en) | Compositions for delivery of antisense compounds | |
| EA201691421A1 (ru) | Гетероарилы и их применение | |
| EA201792496A1 (ru) | Способы лечения воспаления или нейропатической боли | |
| DK3773558T3 (da) | Kombinationsbehandling af artritisk sygdom | |
| DK3846810T3 (da) | Kronisk aftendosering af lasmiditan for migræneforebyggelse | |
| DK3573620T3 (da) | Sammensætninger til behandling af hypertension | |
| IL287832A (en) | Methods of administering anti-cd38 antibody to treat multiple myeloma | |
| EA201690790A1 (ru) | Серосодержащее бициклическое соединение | |
| DK3897455T3 (da) | Medicinsk fastgørelsesindretning til fastgørelse af transplantaert | |
| DK4518970T3 (da) | Anvendelse af myostatinhæmmer til behandling af spinal muskelatrofi | |
| IL312635A (en) | Pharmaceutical combinations for treatment of hbv | |
| DK3784237T3 (da) | Indretning til transdermal levering af tetrabenazin | |
| DK4007777T5 (da) | Car-t-celler mod bcma til behandlingen af myelomatose | |
| DK4058148T3 (da) | Doseringsregime for anti-bcma-midler | |
| DK3914620T3 (da) | Behandling af t-cellelymfom | |
| KR102490400B9 (ko) | 골관절염 예방 또는 치료용 약학 조성물 | |
| HUE053924T2 (hu) | Kompozíció cukorbetegség kezelésére | |
| DK4179153T3 (da) | Fremgangsmåde til behandling af jord | |
| DK3743043T3 (da) | Farmaceutiske sammensætninger til behandling af post-operative smerter | |
| DK3962494T3 (da) | Pulserende gnrh-administration til behandling af kognitive forstyrrelser | |
| EP4010302C0 (en) | PLASTER TREATMENT COMPOUND | |
| DK4021505T3 (da) | Medikament til behandling af infektionssygdomme | |
| DK3955933T3 (da) | Behandling af migræne |